The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) released an update to their 2019 guidelines on the diagnosis and treatment of multiple sclerosis (MS). A panel of experts who manage MS in the MENA region issued the revised 2023 guideline published in the journal Multiple Sclerosis and Related Disorders. Consider treatment for patients with RIS if they have multiple risk factors and evidence of new lesions. Related ContentRelapsing-Remitting Multiple Sclerosis (RRMS)There are over 20 disease modifying therapies (DMTs) that are approved for the treatment of RRMS. Multiple Sclerosis in MENA RegionsWith the increase in MS incidence and prevalence worldwide, including the MENA regions, the establishment of specific guidelines becomes increasingly important.
